Ascendis Pharma A/S
ASND
Peringkat dalam Saham
#1502
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Harga Saham
$234.33
Kapitalisasi Pasar
$14.62B
Perubahan (1 hari)
1.90%
Perubahan (1 tahun)
14.19%
Negara
DK
Perdagangan Ascendis Pharma A/S (ASND)
Kategori
Healthcare
Rasio P/S untuk Ascendis Pharma A/S (ASND)
Rasio P/S per October 2026 TTM: 11.93
Menurut laporan keuangan dan harga saham terbaru dari Ascendis Pharma A/S, rasio P/S saat ini (TTM) adalah 11.93. Pada akhir 2023, rasio P/S perusahaan adalah 24.05.
Riwayat rasio P/S untuk Ascendis Pharma A/S dari 2011 hingga 2026
Rasio P/S pada akhir setiap tahun
| Tahun | Rasio P/S | Mengubah |
|---|---|---|
| 2026 (TTM) | 11.93 | -43.64% |
| 2024 | 21.17 | -11.98% |
| 2023 | 24.05 | -80.76% |
| 2022 | 124.97 | -85.00% |
| 2021 | 833.09 | -16.14% |
| 2020 | 993.40 | 130.30% |
| 2019 | 431.35 | 103.35% |
| 2018 | 212.13 | -70.89% |
| 2017 | 728.64 | 557.34% |
| 2016 | 110.85 | 125.22% |
| 2015 | 49.22 | 161.17% |
| 2014 | 18.84 | 160.08% |
| 2013 | 7.25 | -26.75% |
| 2012 | 9.89 | 0.00% |
| 2011 | 0.00 | 0.00% |
Rasio P/S untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/S | Perbedaan Rasio P/S | Negara |
|---|---|---|---|
| 10.02 | -16.00% |
US
|
|
| 40.55 | 239.89% |
US
|
|
| 3.96 | -66.80% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -14.96% |
NL
|
